| Symbol | ASMB |
|---|---|
| Name | ASSEMBLY BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | TWO TOWER PLACE,7TH FLOOR, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 833 509-4583 |
| Fax | — |
| — | |
| Website | https://www.assemblybio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001426800 |
| Description | Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The companys HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program. Additional info from NASDAQ: |
Gaggar Anuj 🟢 acquired 14.0K shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) Transaction Date: Mar 29, 2026 | Filing ID: 259927
Read moreWhite Nicole S 🟢 acquired 14.0K shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) Transaction Date: Mar 29, 2026 | Filing ID: 259924
Read moreMcHutchison John G 🟢 acquired 8.0K shares (1 derivative) of ASSEMBLY BIOSCIENCES, INC. (ASMB) at $24.11 Transaction Date: Jun 04, 2026 | Filing ID: 259855
Read moreMahony Susan 🟢 acquired 8.0K shares (1 derivative) of ASSEMBLY BIOSCIENCES, INC. (ASMB) at $24.11 Transaction Date: Jun 04, 2026 | Filing ID: 259822
Read moreJohnson-Pratt Lisa 🟢 acquired 8.0K shares (1 derivative) of ASSEMBLY BIOSCIENCES, INC. (ASMB) at $24.11 Transaction Date: Jun 04, 2026 | Filing ID: 259808
Read moreConsylman Gina 🟢 acquired 8.0K shares (1 derivative) of ASSEMBLY BIOSCIENCES, INC. (ASMB) at $24.11 Transaction Date: Jun 04, 2026 | Filing ID: 259742
Read moreALTIG ANTHONY E 🟢 acquired 8.0K shares (1 derivative) of ASSEMBLY BIOSCIENCES, INC. (ASMB) at $24.11 Transaction Date: Jun 04, 2026 | Filing ID: 259697
Read moreBjorkquist Jeanette M 🟢 acquired 3.5K shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) Transaction Date: Mar 29, 2026 | Filing ID: 259661
Read moreDelaney William E IV 🟢 acquired 14.0K shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) Transaction Date: Mar 29, 2026 | Filing ID: 259562
Read moreOkazaki Jason A 🟢 acquired 50.8K shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) Transaction Date: Mar 29, 2026 | Filing ID: 259517
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07208422 | Task-Specific Self-Rehabilitation Training (TASSRET) Trial | Na | Stroke | Completed | 2025-06-07 | 2026-02-21 | ClinicalTrials.gov |
| NCT06740474 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in … | Phase1 | Hepatitis Delta Virus | Completed | 2025-01-31 | 2025-07-08 | ClinicalTrials.gov |
| NCT06698575 | A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in… | Phase1 | Recurrent Genital Herpes Simplex Type 2 | Completed | 2024-12-08 | 2026-01-19 | ClinicalTrials.gov |
| NCT06384131 | A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4… | Phase1 | Chronic Hepatitis B | Completed | 2024-06-04 | 2025-05-14 | ClinicalTrials.gov |
| NCT06385327 | A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5… | Phase1 | Recurrent Genital Herpes Simplex Type 2 | Completed | 2024-05-30 | 2026-02-03 | ClinicalTrials.gov |
| NCT05569941 | A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-… | Phase1 | Chronic Hepatitis B | Completed | 2022-11-11 | 2023-04-12 | ClinicalTrials.gov |
| NCT05414981 | A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H… | Phase1 | Chronic Hepatitis B | Completed | 2022-08-07 | 2023-04-24 | ClinicalTrials.gov |
| NCT04781647 | A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With C… | Phase2 | Chronic Hepatitis B | Terminated | 2021-02-18 | 2022-12-02 | ClinicalTrials.gov |
| NCT04637139 | A Study to Evaluate the Mass Balance Absorption and AME of VBR | Phase1 | Chronic Hepatitis B | Completed | 2020-12-01 | 2020-12-22 | ClinicalTrials.gov |
| NCT04454567 | A Study Evaluating Treatment Intensification With ABI-H0731 in Participants Wit… | Phase2 | Chronic Hepatitis B | Terminated | 2020-11-11 | 2021-04-08 | ClinicalTrials.gov |
| NCT04398134 | A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis… | Phase2 | Chronic Hepatitis B | Terminated | 2020-08-28 | 2021-12-28 | ClinicalTrials.gov |
| NCT04271592 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in He… | Phase1 | Chronic Hepatitis B | Completed | 2020-05-17 | 2021-01-14 | ClinicalTrials.gov |
| NCT04142762 | A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug In… | Phase1 | Chronic Hepatitis B | Completed | 2019-10-18 | 2020-01-29 | ClinicalTrials.gov |
| NCT04083716 | A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in … | Phase1 | Chronic Hepatitis B | Completed | 2019-09-06 | 2019-10-07 | ClinicalTrials.gov |
| NCT03923478 | ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis | Phase1 | Ulcerative Colitis Chronic Mild | Terminated | 2019-06-24 | 2021-01-20 | ClinicalTrials.gov |
| NCT03780543 | A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis … | Phase2 | Chronic Hepatitis B | Terminated | 2018-12-20 | 2021-04-26 | ClinicalTrials.gov |
| NCT03714152 | A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B | Phase1 | Chronic Hepatitis B | Completed | 2018-11-13 | 2021-01-07 | ClinicalTrials.gov |
| NCT03577171 | A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of… | Phase2 | Chronic Hepatitis B | Completed | 2018-06-19 | 2019-06-21 | ClinicalTrials.gov |
| NCT03576066 | A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic… | Phase2 | Chronic Hepatitis B | Completed | 2018-06-11 | 2019-07-05 | ClinicalTrials.gov |
| NCT03109730 | Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B | Phase1 | Chronic Hepatitis B | Completed | 2017-06-15 | 2018-06-12 | ClinicalTrials.gov |
| NCT02908191 | A Study in Healthy Volunteers and Patients With Chronic Hepatitis B | Phase1 | Chronic Hepatitis B | Completed | 2016-11-01 | 2018-06-12 | ClinicalTrials.gov |
| NCT02234973 | Transformation of Indigenous Primary Healthcare Delivery | — | Type 2 Diabetes Mellitus | Completed | 2014-09-01 | 2020-03-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Manual-based Task-specific Training | Other | Approved | Stroke | COMPLETED | NCT07208422 |
| Video-based Task-specific Training | Other | Approved | Stroke | COMPLETED | NCT07208422 |
| Quality Improvement | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02234973 |
| Quality Improvement | Other | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02234973 |
| Pegasys | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT03109730 |
| Tenofovir Disoproxil Fumarate | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT03109730 |
| Entecavir | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT03109730 |
| Placebo for ABI-H0731 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT03109730 |
| ABI-H0731 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT03109730 |
| Nucleos(t)ide | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT02908191 |
| Pegasys | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT02908191 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT02908191 |
| Entecavir | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT02908191 |
| Placebo for ABI-H0731 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT02908191 |
| ABI-H0731 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT02908191 |
| ABI-H2158 Test Formulation | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04083716 |
| ABI-H2158 Reference Formulation | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04083716 |
| Placebo matching oral contraceptive | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04142762 |
| Esomeprazole | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04142762 |
| Ethinyl Estradiol / Levonorgestrel | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04142762 |
| Midazolam | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04142762 |
| Rifampin | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04142762 |
| Itraconazole | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04142762 |
| ABI-H2158 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04142762 |
| Vebicorvir (VBR) | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04637139 |
| Placebo to ABI-H3733 Solid Oral Dosage Form | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04271592 |
| Placebo to ABI-H3733 Liquid Oral Dosage Form | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04271592 |
| ABI-H3733 Solid Oral Dosage Form | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04271592 |
| ABI-H3733 Liquid Oral Dosage Form | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04271592 |
| Placebo for ABI-H2158 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT03714152 |
| ABI-H2158 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT03714152 |
| Placebo Oral Tablet | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03577171 |
| SOC ETV | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03577171 |
| ABI-H0731 | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03577171 |
| Placebo Oral Tablet | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03576066 |
| SOC NUC | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03576066 |
| ABI-H0731 | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03576066 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis Chronic Mild | TERMINATED | NCT03923478 |
| ABI-M201 | Other | Phase PHASE1 | Ulcerative Colitis Chronic Mild | TERMINATED | NCT03923478 |
| Entecavir (ETV) | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT04398134 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT04398134 |
| ABI-H2158 | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT04398134 |
| NrtI | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT04454567 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT04454567 |
| ABI-H0731 | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT04454567 |
| standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI) | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT03780543 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05414981 |
| ABI-H3733 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05414981 |
| ABI-4334 Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05569941 |
| ABI-4334 Tablet | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05569941 |
| Peg-IFNα | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT04781647 |
| ETV | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT04781647 |
| ABI-H0731 | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT04781647 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT06384131 |
| ABI-4334 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT06384131 |
| Placebo | Other | Phase PHASE1 | Hepatitis Delta Virus | COMPLETED | NCT06740474 |
| ABI-6250 | Other | Phase PHASE1 | Hepatitis Delta Virus | COMPLETED | NCT06740474 |
| ABI-1179 Placebo | Other | Phase PHASE1 | Recurrent Genital Herpes Simplex Type 2 | COMPLETED | NCT06698575 |
| ABI-1179 | Other | Phase PHASE1 | Recurrent Genital Herpes Simplex Type 2 | COMPLETED | NCT06698575 |
| ABI-5366 Placebo | Other | Phase PHASE1 | Recurrent Genital Herpes Simplex Type 2 | COMPLETED | NCT06385327 |
| ABI-5366 | Other | Phase PHASE1 | Recurrent Genital Herpes Simplex Type 2 | COMPLETED | NCT06385327 |
| Quality Improvement | BEHAVIORAL | Preclinical | Type 2 Diabetes Mellitus | COMPLETED | NCT02234973 |